Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.44 USD | -1.53% | -8.26% | -13.98% |
May. 09 | UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating | MT |
May. 08 | Transcript : REGENXBIO Inc., Q1 2024 Earnings Call, May 08, 2024 |
End-of-day quotes
Sector Bio Therapeutic Drugs
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
761M | - | |||||
109B | ||||||
105B | ||||||
22.25B | - | |||||
22.09B | - | |||||
18.68B |
- Stock Market
- Equities
- RGNX Stock
- Charts REGENXBIO Inc.
- Sector Chart